Carbon Dots for Next-Generation Cancer Theranostics: From Advanced Imaging to Targeted Therapy.
1/5 보강
Quasi-spherical fluorescent carbon dots (CDs) have gained attention as a powerful tool in cancer theranostics due to their exceptional optical properties, biocompatibility, and tunable surface functio
APA
Patyal R, Warjurkar K, Sharma V (2025). Carbon Dots for Next-Generation Cancer Theranostics: From Advanced Imaging to Targeted Therapy.. ACS applied bio materials, 8(12), 10576-10602. https://doi.org/10.1021/acsabm.5c01797
MLA
Patyal R, et al.. "Carbon Dots for Next-Generation Cancer Theranostics: From Advanced Imaging to Targeted Therapy.." ACS applied bio materials, vol. 8, no. 12, 2025, pp. 10576-10602.
PMID
41213180 ↗
Abstract 한글 요약
Quasi-spherical fluorescent carbon dots (CDs) have gained attention as a powerful tool in cancer theranostics due to their exceptional optical properties, biocompatibility, and tunable surface functionalities. This review focuses on the diverse roles of CDs in cancer diagnostics and therapies. CDs are increasingly being explored for their applications in various cancer therapies, such as in photodynamic therapy (PDT), photothermal therapy (PTT), photocatalytic therapy (PCT), sonodynamic therapy (SDT), drug delivery systems, and advanced imaging techniques, such as magnetic resonance imaging (MRI) and photoacoustic imaging (PAI). By integrating multimodal therapeutic strategies, CDs help to overcome various challenges such as tumor hypoxia, drug resistance, and off-target effects, facilitating more precise cancer treatments. Furthermore, recent advancements in surface modification and functionalization have improved the selectivity, efficacy, and safety of CDs, enabled better targeting of tumors, and enhanced treatment outcomes. This review emphasizes the potential of CDs to combine diagnostic and therapeutic functions, offering exciting possibilities for the future of cancer cure.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.